The acquisition follows OmniComm’s purchase of eResearch Technologies’ (ERT) EDC assets. By making the acquisitions OmniComm believes it has strengthened and broadened the scope of its offering in a market that it predicts will enjoy long-term growth.
Discussing the acquisition of Logos’ assets, Cornelis Wit, OmniComm's CEO, explained: “Larger pharmaceutical companies in particular will be a prime consumer of this product.
“This combined with our recent acquisition of ERT’s data capture unit, positions us well to offer our clients a wide array of state of the art, cost-effective tools to capture and track outcomes of clinical trials."
OmniComm’s acquisition of assets from Logos moves it into the Phase I trials market, which it has identified as a sector that few companies specialise in.
Data collection in Phase I is very-time controlled and this means EDC systems need different abilities. To tailor its EDC system to Phase I Logos uses proactive data collection, which OmniComm regards as imperative for early-stage trials.
Logos is one of just three companies that markets EDC systems with proactive data collection, according to OmniComm. Consequently, the acquisition of these assets puts OmniComm in a strong position in the Phase I EDC market.
Citing Health Industry Insights OmniComm states that the Phase I EDC market will be worth $120m (€83.4m) by 2010.
Furthermore, OmniComm believes the Phase I market is one of the fastest growing segments of clinical research and that this will translate into increased demand for early-stage EDC systems.
The acquisition will be operated by OmniComm’s subsidiary in the UK.